LMBA02 Protocol for Patients With a Burkitt Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2006 by Gustave Roussy, Cancer Campus, Grand Paris.
Recruitment status was  Recruiting
Information provided by:
Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov Identifier:
First received: September 12, 2005
Last updated: September 7, 2006
Last verified: September 2006
To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.

Condition Intervention Phase
Burkitt Lymphoma
Drug: rituximab
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Gustave Roussy, Cancer Campus, Grand Paris:

Primary Outcome Measures:
  • Event free survival from date of first randomization

Secondary Outcome Measures:
  • Complete and partial response rate, overall survival, toxicity

Estimated Enrollment: 260
Study Start Date: October 2004

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age : 18 years or older
  • Histologically or cytologically proven Burkitt lymphoma according to the WHO classification
  • WHO performance < 3
  • Informed consent

Exclusion Criteria:

  • Known HIV positive infection
  • Positive serology for HCV and HBV (except after vaccination)
  • Patients previously treated for lymphoma
  • cardiac disease that contradict anthracycline chemotherapy
  • Psychological or psychiatric condition who contradict steroids therapy
  • Patients with serious renal failure unrelated to the lymphoma (serum creatinin level higher than 150 mmole/L)
  • Cirrhosis or severe hepatic failure unrelated to the lymphoma
  • Previous malignant disease except basal cell skin carcinoma or in situ uterine cervix carcinoma
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Primary organ transplant or other immunosuppressive conditions Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180882

Contact: Vincent RIBRAG, MD 33 1 42 11 43 47 ribrag@igr.fr

Institut Gustave Roussy Recruiting
Villejuif, France, 94800
Contact: Vincent RIBRAG, MD    33 1 42 11 43 47    ribrag@igr.fr   
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Principal Investigator: Vincent RIBRAG, MD Gustave Roussy, Cancer Campus, Grand Paris
  More Information

ClinicalTrials.gov Identifier: NCT00180882     History of Changes
Other Study ID Numbers: LMBA02 
Study First Received: September 12, 2005
Last Updated: September 7, 2006
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Burkitt Lymphoma
DNA Virus Infections
Epstein-Barr Virus Infections
Herpesviridae Infections
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Tumor Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on May 23, 2016